Through laboratory techniques that track quantities of mRNA, scientists can identify which genes are “turned on” and which are “turned off” in an organism’s tissue at a given time, as ...

BRISBANE, Calif., March 11, 2025--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of ...

The new MessageBOOSTER cDNA Synthesis from Cell Lysates kit eliminates these difficulties by enabling RNA amplification and cDNA synthesis directly from cell lysates, without the need to purify ...

CareDx (CDNA) reported $86.58 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 32%. EPS of $0.18 for the same period compares to -$0.17 a year ago.

CareDx, Inc (NASDAQ:CDNA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on CareDx (CDNA – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $19.27.

Prudential Financial Inc. boosted its position in shares of CareDx, Inc (NASDAQ:CDNA – Free Report) by 58.5% in the 4th quarter, according to the company in its most recent 13F filing with the ...